PB1847: A PHASE 1 STUDY TO INVESTIGATE CLN-049, A FLT3/CD3 BISPECIFIC T CELL ENGAGER, IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) ACUTE MYELOID LEUKEMIA (AML) OR MYELODYSPLASTIC SYNDROME (MDS)

• Maher Abdul-Hay,
• Courtney Dinardo,
• Onyee Chan,
• Rupa Narayan,
• Ghayas Issa,
• Jennifer Michaelson,
• Patrick Baeuerle,
• Kristan Meetze,
• John Janik,
• Irina Shapiro,
• Judy Inumerable,
• Jeffery Jones,
• David Sallman

Affiliations

Maher Abdul-Hay

1 New York University Langone Health, Blood and Marrow Transplantation and Cellular Therapy, New York, United States

Courtney Dinardo

2 The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, United States

Onyee Chan

3 H. Lee Moffitt Cancer Center and Research Institute, Department of Malignant Hematology, Tampa, United States

Rupa Narayan

4 Mass General Cancer Center, Department of Hematology/Oncology, Cambridge, United States

Ghayas Issa

2 The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, United States

Jennifer Michaelson

5 Cullinan Oncology, Cambridge, United States

Patrick Baeuerle

5 Cullinan Oncology, Cambridge, United States

Kristan Meetze

5 Cullinan Oncology, Cambridge, United States

John Janik

5 Cullinan Oncology, Cambridge, United States

Irina Shapiro

5 Cullinan Oncology, Cambridge, United States

Judy Inumerable

5 Cullinan Oncology, Cambridge, United States

Jeffery Jones

5 Cullinan Oncology, Cambridge, United States

David Sallman

3 H. Lee Moffitt Cancer Center and Research Institute, Department of Malignant Hematology, Tampa, United States